Rheumatology Advance Access originally published online on May 3, 2007
Rheumatology 2007 46(7):1126-1132; doi:10.1093/rheumatology/kem090
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout
Orthopaedic University Clinic, Bochum, Germany, 1OMI, Buenos Aires, Argentina, 2Isselburg, 3Deggingen, Germany, 4Novartis Pharma AG, Basel, Switzerland and 5Novartis Pharma GmbH, Nuremberg, Germany.
Correspondence to: E. Mysler, University of Buenos Aires, Uruguay 725, Buenos Aires (1015), Argentina. E-mail: emysler{at}attglobal.net
 |
Abstract |
|---|
Objectives. To demonstrate non-inferiority of lumiracoxib 400 mg once daily (o.d.) compared with indomethacin 50 mg three times daily (t.i.d.) in the treatment of acute gout, and to compare the safety and tolerability of these treatments.
Methods. In this 1-week, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study, patients with a clinical diagnosis of gout, an acute attack of gout in four or more joints within the 48 h prior to evaluation, and at least moderate pain intensity in the target joint were randomized to treatment with lumiracoxib 400 mg o.d. (n = 118) or indomethacin 50 mg t.i.d. (n = 117). The primary efficacy endpoint was the mean change in pain intensity from baseline over days 2–5, assessed on a 5-point Likert scale, where non-inferiority could be claimed if the lower limit of the confidence interval (CI) was greater than –0.5. The patient's and physician's global assessment of response to treatment, and physician's assessment of tenderness, swelling and erythema of the study joint were also assessed.
Results. The estimated difference between treatments for the change from baseline in pain intensity over days 2–5 was –0.004 (95% CI –0.207 to 0.199, P > 0.05), indicating that lumiracoxib 400 mg o.d. had comparable efficacy to indomethacin 50 mg t.i.d. for the primary efficacy variable. There was no significant difference between treatments in any of the secondary efficacy variables. Adverse events were reported by 10.2% of patients treated with lumiracoxib and 22.2% of those receiving indomethacin.
Conclusions. Lumiracoxib is as effective as indomethacin for treatment of acute gout and may have a better safety and tolerability profile.
Submitted 9 November 2006;
revised version accepted 19 March 2007.
CiteULike 
Connotea 
Del.icio.us What's this?